Alnylam Pharmaceuticals
ALNY
#1011
Rank
$19.00 B
Marketcap
$150.24
Share price
0.56%
Change (1 day)
-22.18%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2023 (TTM): -$0.32 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings (TTM) are -$0.2 B. an increase over its 2022 earnings that were of -$0.98 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2023

Annual earnings

Year Earnings Change
2023 -$0.32 B-67.84%
2022 -$0.98 B36.93%
2021 -$0.71 B-8.04%
2020 -$0.78 B-15.66%
2019 -$0.92 B12.23%
2018 -$0.82 B62.91%
2017 -$0.51 B17.78%
2016 -$0.43 B43.44%
2015 -$0.3 B60.69%
2014 -$0.19 B98.2%
2013 -$92.95 M
2011 -$54.82 M27.48%
2010 -$43.01 M-10.92%
2009 -$48.28 M95.77%
2008 -$24.66 M
2006 -$39.51 M-9.13%
2005 -$43.48 M34.74%
2004 -$32.27 M36.79%
2003 -$23.59 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
$9.82 B-5,082.68%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$7.26 B-3,781.52%๐Ÿ‡ซ๐Ÿ‡ท France
$4.04 B-2,149.46%๐Ÿ‡บ๐Ÿ‡ธ USA
$34.06 M-117.27%๐Ÿ‡บ๐Ÿ‡ธ USA
-$29.44 M-85.08%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.19 B-6.54%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.40 B-305.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
-$0.29 B 43.26%๐Ÿ‡บ๐Ÿ‡ธ USA